# Paolo Di Giorgio

> Paolo Di Giorgio is a Series A investor at Angelini Ventures backing Therapeutics and Health Care. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Angelini Ventures](https://shizune.co/investors/profile/angelini-ventures)
- Location: Rome, Italy
- Total investments: 4
- Last investment: Mar 2024
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/francescopaolodigiorgio/

Paolo Di Giorgio is a Series A investor at Angelini Ventures in Rome focused on Therapeutics and Health Care. Paolo Di Giorgio is the Chief Executive Officer and Managing Director of Angelini Ventures. He previously worked at Angelini Pharma as a Head of R&D and External Innovation. Paolo Di Giorgio attended Harvard University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 3 | 75% |
| Health Care | 2 | 50% |
| Biotechnology | 2 | 50% |
| Women's | 1 | 25% |
| Genetics | 1 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Series B | 1 | 25% |
| Series C | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 75% |
| Switzerland | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nouscom | Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy.The NousCom team is lead by experiencedenterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies. | $7.6M | Series C | Mar 21, 2024 |  |
| Freya Biosciences | Freya Biosciences is a clinical-stage women’s health company pioneering a new class of microbial immunotherapies. It is based in Copenhagen and Boston. | $38M | Series A | Dec 12, 2023 |  |
| Cadence Neuroscience | Cadence Neuroscience is an early-stage company developing new medical device therapies for the treatment of epilepsy, central pain, and other neurological disorders. The company's core technology has been developed at Mayo Clinic and is under clinical evaluation. Its medical device therapies provide medical practitioners with the procedurethat can be used to tailor brain stimulation therapy to each individual and enhance seizure control compared to currently used protocols.Cadence Neuroscience was established in 2017 and is headquartered in Redmond, Washington. | $26M | Series B | Feb 28, 2023 |  |
| Pretzel Therapeutics | Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinatingfeatures that make it unlike any other organelle in the body. | $72.5M | Series A | Sep 12, 2022 |  |

4 of 4 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 3 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 2 deals together
- [Jazz Venture Partners](https://shizune.co/investors/profile/jazz-venture-partners) — VC Fund, 2 deals together
- [Mubadala Capital Ventures](https://shizune.co/investors/profile/mubadala-ventures) — VC Fund, 2 deals together
- [Angelini Lumira Biosciences Fund](https://shizune.co/investors/profile/angelini-lumira-biosciences-fund) — VC Fund, 1 deal together
- [Cambridge Innovation Capital](https://shizune.co/investors/profile/cambridge-innovation-capital) — VC Fund, 1 deal together

## About Angelini Ventures

VC Fund · Rome, Italy

Angelini Ventures is an investment firm.

5 contacts available at Angelini Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Nils Bottler | Principal | https://shizune.co/investors/profile/nils-bottler |
| Paolo Di Giorgio | Chief Executive Officer & Managing Director | https://shizune.co/investors/profile/paolo-di-giorgio |
| Regina Hodits | Managing Director | https://shizune.co/investors/profile/regina-hodits |
| Sarah Fox | Investor | https://shizune.co/investors/profile/sarah-fox-5abb |
| Sergio Di Condojanni | Chief Executive Officer | https://shizune.co/investors/profile/sergio-marullo-di-condojanni |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Paolo Di Giorgio invest in?

Paolo Di Giorgio invests primarily in Therapeutics, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Paolo Di Giorgio last invest?

The most recent investment recorded for Paolo Di Giorgio closed in Mar 2024. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co